Literature DB >> 35595919

Outcomes of heart transplantation in cardiac amyloidosis: an updated systematic review.

Sofia Lakhdar1, Chandan Buttar2, Mahmood Nassar3, Camelia Ciobanu4, Rima Patel5, Most Sirajum Munira5,6.   

Abstract

Cardiac amyloidosis is one of the most common infiltrative cardiomyopathies that is characterized by the extracellular deposition of misfolded fibrillar protein. Several studies have previously found that patients with amyloid in the past have performed poorly after heart transplantation. Recent advancements in treatments have been made that have significantly improved outcomes in these patients. The study aimed to evaluate the outcomes of heart transplantation in cardiac amyloidosis. We systematically searched EMBASE, PubMed/MEDLINE, and Cochrane Library databases on 30 December 2021 following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. We identified 22 studies that examined 42,951 patients with cardiac amyloidosis of which only 1,329 patients underwent isolated heart transplantation. Seven studies reported individual patient data. The results of 123 patients have been pooled for analysis. There were 70 male patients, 45 female patients, and eight patients who did not report their gender. Among the types of amyloids, 63 (51%) patients were found to have light chain amyloidosis (AL) and 33 (27%) patients had transthyretin amyloidosis (ATTR). Only 41 patients (33.3%) reported a monoclonal component. There were 30 patients with AL that underwent autologous hematopoietic stem cell transplant (ASCT). The mean survival of 24 out of 30 patients was 4.33 years. In addition, the reported data include 13 patients requiring intra-aortic balloon pump (IABP), six with cardiac resynchronization therapy (CRT), and four with implantable cardioverter defibrillator (ICD). With the current advancements in treatments in combination with a multidisciplinary approach and careful patient selection, patients undergoing heart transplantation for amyloidosis may have encouraging results in the current era. Further studies will be needed to evaluate the outcomes of heart transplantation in amyloidosis patients now that several advances have been made in the field.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac amyloidosis; Heart failure; Heart transplantation; Infiltrative cardiomyopathy

Mesh:

Year:  2022        PMID: 35595919     DOI: 10.1007/s10741-022-10252-8

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN: 1382-4147            Impact factor:   4.654


  20 in total

1.  Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.

Authors:  Angela Dispenzieri; Robert A Kyle; Martha Q Lacy; Terry M Therneau; Dirk R Larson; Matthew F Plevak; S Vincent Rajkumar; Rafael Fonseca; Philip R Greipp; Thomas E Witzig; John A Lust; Steven R Zeldenrust; Denise S Snow; Susan R Hayman; Mark R Litzow; Dennis A Gastineau; Ayalew Tefferi; David J Inwards; Ivana N Micallef; Stephen M Ansell; Luis F Porrata; Michelle A Elliott; Morie A Gertz
Journal:  Blood       Date:  2004-01-22       Impact factor: 22.113

Review 2.  Cardiac amyloidosis: what are the indications for transplant?

Authors:  Scott H Bradshaw; John P Veinot
Journal:  Curr Opin Cardiol       Date:  2012-03       Impact factor: 2.161

Review 3.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review.

Authors:  Frederick L Ruberg; Martha Grogan; Mazen Hanna; Jeffery W Kelly; Mathew S Maurer
Journal:  J Am Coll Cardiol       Date:  2019-06-11       Impact factor: 24.094

4.  Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.

Authors:  Christopher D Barrett; Kevin M Alexander; Hongyu Zhao; Francois Haddad; Paul Cheng; Ronglih Liao; Matthew T Wheeler; Michaela Liedtke; Stanley Schrier; Sally Arai; Dana Weisshaar; Ronald M Witteles
Journal:  JACC Heart Fail       Date:  2020-05-06       Impact factor: 12.035

Review 5.  Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.

Authors:  Ronald M Witteles; Sabahat Bokhari; Thibaud Damy; Perry M Elliott; Rodney H Falk; Nowell M Fine; Mariana Gospodinova; Laura Obici; Claudio Rapezzi; Pablo Garcia-Pavia
Journal:  JACC Heart Fail       Date:  2019-07-10       Impact factor: 12.035

6.  Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study.

Authors:  Tania Jain; Heidi E Kosiorek; Shu T Kung; Vishal S Shah; Amylou C Dueck; Veronica Gonzalez-Calle; Susan Luft; Craig B Reeder; Roberta Adams; Pierre Noel; Jeremy T Larsen; Joseph Mikhael; Leif Bergsagel; A Keith Stewart; Rafael Fonseca
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-05-04

7.  Heart transplantation in patients with amyloidosis: single-center experience.

Authors:  A Alloni; C Pellegrini; T Ragni; C Goggi; A M D'Armini; M Rinaldi; M Viganò
Journal:  Transplant Proc       Date:  2004-04       Impact factor: 1.066

8.  High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.

Authors:  Martha Skinner; Vaishali Sanchorawala; David C Seldin; Laura M Dember; Rodney H Falk; John L Berk; Jennifer J Anderson; Carl O'Hara; Kathleen T Finn; Caryn A Libbey; Janice Wiesman; Karen Quillen; Niall Swan; Daniel G Wright
Journal:  Ann Intern Med       Date:  2004-01-20       Impact factor: 25.391

9.  Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy.

Authors:  Martha Q Lacy; Angela Dispenzieri; Suzanne R Hayman; Shaji Kumar; Robert A Kyle; S Vincent Rajkumar; Brooks S Edwards; Richard J Rodeheffer; Robert P Frantz; Sudhir S Kushwaha; Alfredo L Clavell; Joseph A Dearani; Thoralf M Sundt; Richard C Daly; Christopher G A McGregor; Dennis A Gastineau; Mark R Litzow; Morie A Gertz
Journal:  J Heart Lung Transplant       Date:  2008-07-03       Impact factor: 10.247

10.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.

Authors:  Mathew S Maurer; Jeffrey H Schwartz; Balarama Gundapaneni; Perry M Elliott; Giampaolo Merlini; Marcia Waddington-Cruz; Arnt V Kristen; Martha Grogan; Ronald Witteles; Thibaud Damy; Brian M Drachman; Sanjiv J Shah; Mazen Hanna; Daniel P Judge; Alexandra I Barsdorf; Peter Huber; Terrell A Patterson; Steven Riley; Jennifer Schumacher; Michelle Stewart; Marla B Sultan; Claudio Rapezzi
Journal:  N Engl J Med       Date:  2018-08-27       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.